Aim: The increased risk of hepatocellular carcinoma (HCC) recurrence in hepatitis C virus (HCV)-infected patients treated with direct-acting antivirals (DAAs) after curative treatment for HCC is controversial. The purpose of this study was to examine the risk of HCC recurrence after DAA therapy.
INTRODUCTION
Worldwide, primary liver cancer is the second and sixth leading cause of cancer mortality in men and women, respectively [1, 2] . The most frequent cause of HCC is liver cirrhosis due to HCV infection [3] . DAA therapy have made it possible for most patients with HCV infection to achieve a sustained virological response, even if they cannot tolerate interferon-based therapy. The introduction of DAA therapy is expected to improve the prognosis of patients with liver cirrhosis due to HCV infection, and it is also expected that the recurrence rate will decrease in patients after HCC treatment. However, recent studies have suggested that DAA therapy might increase the risk of HCC recurrence [4, 5] . For example, a Spanish multicenter study reported by Reig et al. [4] warned that DAA therapy may increase the risk of HCC recurrence. In their paper, 16/58 (27.6%) patients who received DAA therapy after HCC treatment experienced tumor recurrence after a median follow-up period of 5.7 months. Subsequently, several studies reporting contradictory findings have been published [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Although DAAs have been demonstrated to lower carcinogenicity in patients without a history of HCC treatment [8, 16] , the effect of DAAs for preventing recurrence after HCC treatment has not been proven. In this study, we investigated the outcomes of HCC patients who received DAA therapy after curative treatment with hepatectomy or radio-frequency ablation (RFA) in a multicenter collaborative study and attempted to elucidate the effect of DAAs on recurrence.
METHODS

Patients
We performed a multicenter, retrospective cohort analysis of HCC patients who had previously been treated with hepatectomy or RFA and who received anti-HCV treatment with DAAs between September 2014 and July 2016. In this study, 312 consecutive patients were enrolled: 224 (71.8%) and 88 (28.2%) patients received RFA and hepatectomy before DAA treatment, respectively. A flowchart of the patient selection is shown in the Supplementary Figure 1 .
All patients were diagnosed as cancer-free prior to DAA treatment based on triple-phase multidetector computed tomography (CT), dynamic contrast-enhanced magnetic resonance imaging (MRI) or ultrasonography (US). We confirmed the cancer-free status at least with two imaging modalities. The study protocol conformed to the ethical guidelines of the World Medical Association and the Declaration of Helsinki and was approved by the ethics committees of each institute.
DAA treatment
The DAA regimens were daclatasvir/asnaprevir (n = 130, 41.7%), sofosbuvir/ledipasvir (n = 116, 37.2%), sofosbuvir/ ribavirin (n = 61, 19.6%) and ombitasvir/paritaprevir/ritonavir (n = 5, 1.6%). We assessed the response to DAA treatment based on the presence of HCV-RNA at 12 weeks after the end of the treatment. Patients negative for HCV-RNA at this time were considered to have achieved a sustained virological response (SVR12). The presence of HCV-RNA was examined using real-time polymerase chain reaction.
Follow-up
After DAA treatment, the patients were assessed every three months by US, triple-phase CT, or MRI. The diagnosis of HCC recurrence was confirmed via typical HCC imaging patterns obtained by angiography, CT, MRI and US. The criteria for the imaging-based diagnosis of HCC have been described in previous reports: hyper-attenuation at the hepatic arterial phase, hypo-attenuation at the portal venous phase in triple-phase CT or MRI and tumor staining on angiography, or hyper-enhancement in the arterial phase and hypo-enhancement in the portal venous and late phases on contrast-enhanced US [17, 18] .
Statistical analyses
The clinical characteristics of the patients were obtained at the initial treatment for HCC and before and after DAA treatment. The data collected included the age, gender, platelet count, albumin (ALB), total bilirubin (T.Bil), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGTP), prothrombin time-international normalized ratio, Child-Pugh grade, AFP, des-γ-carboxy prothrombin (DCP), lens culinaris agglutinin-reactive AFP-L3, fibrosis (FIB-4) index, HCV genotype, amount of HCV-RNA, history of HCC treatment, number of tumors, maximum diameter of the tumor, date of HCC recurrence, treatment methods and survival.
Patients without recurrence were censored at the last visit or on the date of death. We calculated the annual HCC recurrence rate after DAA therapy and examined the risk factors for recurrence using Cox proportional hazard models. Variables with a P value of ≤ 0.1 in a univariate analysis were incorporated into a multivariate analysis by stepwise selection. The recurrence rate and overall survival rate after DAA therapy were calculated using the Kaplan-Meier method and evaluated with a log-rank test. P values of < 0.05 were considered to indicate statistical significance. All analyses were performed using the JMP Pro 14.1.0 software package (SAS Institute, Inc., Cary, NC, USA). 
RESULTS
Patient characteristics
The clinical characteristics of the patients and the characteristics of HCC before DAA treatment are shown in [Tables 1 and 2 ], respectively. The median age was 74 years old, and 182 (58.3%) patients were male. Two hundred and fifty-one (80.4%) and 60 patients (19.2%) had HCV genotypes 1 and 2, respectively, and 1 patient had both. An SVR12 was achieved by 288 patients (92.3%). The median tumor size at the initial treatment was 18 mm, and 244 patients (78.2%) had a single tumor. The interval from the final HCC treatment and DAA therapy was 297 days (median). The median follow-up time from the end of DAA treatment was 855 days.
The recurrence and survival rates HCC recurred in 135 patients (43.2%), and the 1-, 2-and 3-year cumulative recurrence rates after DAA therapy were 18.3%, 38.8% and 55.4%, respectively [ Figure 1 ]. The 1-, 2-and 3-year-overall survival rates were 99.4%, 98.6% and 95.4%, respectively [ Figure 2 ].
Risk factors for recurrence
In the univariate analysis, the factors associated with HCC recurrence included AFP ≥ 10 ng/mL and multiple tumors at the initial HCC treatment, T.Bil > 0.8 mg/dL, AFP-L3 ≥ 10% at the initiation of DAA therapy, a history of multiple treatments before DAA therapy, RFA as the final HCC treatments before DAA, period between the final HCC treatment and DAA therapy < 1 year, AFP ≥ 10 ng/mL, DCP ≥ 28 mAU/mL, AFP-L3 ≥ 10% and non-SVR12 [ Table 3 ].
In the multivariate analysis, the factors associated with HCC recurrence were multiple tumors at the first HCC treatment [HR = 2.21; 95% confidence interval (CI): 1.41-3.49], a history of multiple treatments for HCC before DAA therapy (HR = 1.97; 95%CI: 1.28-3.02) and AFP-L3 ≥ 10% at the initiation of DAA therapy (HR = 4.74; 95%CI: 2.10-10.7) [ Table 4 ].
The relationship between the number of times the patient had received treatment for HCC and recurrence is shown in [ Figure 3 ]. The recurrence rates increased as the number of previous treatments for HCC increased: the 1-, 2-and 3-year cumulative recurrence rates after DAA therapy were 11.4%, 31.6% and 49.4% in patients with 1 previous treatment; 25.1%, 45.3% and 57.5% in patients with 2-4 previous treatments; and 47.6%, 70.9% and 100% in patients with more than 4 previous treatments, respectively.
Patterns of recurrence
The patterns of HCC recurrence after DAA therapy are shown in [ Table 5 ]. The median diameter of the tumors was 13 mm, and 44 patients (32.6%) had multiple tumors, including 3 patients (2.2%) with extrahepatic metastasis. Two patients (1.5%) had rapidly progressing tumors: 1 had massive infiltrative-growing tumors with invasion to the The treatment methods for HCC after DAA therapy were as follows: RFA (n = 83, 61.4%), hepatectomy (n = 14, 10.4%), TACE (n = 22, 16.3%), radiation therapy (n = 3, 2.2%) and particle beam, percutaneous ethanol injection, hepatic arterial infusion, systemic chemotherapy and best supportive care (n = 1 each).
DISCUSSION
In the present study, we found that the 1-and 3-year recurrence rates of curatively treated HCC patients who received DAA therapy were 18.3% and 55.4%, respectively. In contrast, the 3-year overall survival rate was extremely high (95.4%). In addition, we revealed that the factors associated with recurrence were multiple tumors at the first HCC treatment, a history of multiple treatments for HCC and AFP-L3 ≥ 10% at the initiation of DAA therapy. Table 6 summarizes the published data on HCC recurrence after DAA administration in patients with an HCC treatment history. The unexpectedly high rate of HCC recurrence reported by the Spanish group raised a number of concerns and prompted a great deal of discussion [4] . According to the original paper, 3 patients died, and 16 of 55 patients (27.6%) developed HCC recurrence after a median follow-up period of 5.7 months. However, that group included patients treated with TACE, which was not a curative treatment; recurrence occurred only in cases treated with hepatectomy or RFA before DAA, and no recurrence was reported in cases treated with TACE, possibly because of the small number of TACE cases (only 6). Another Italian group also reported that HCC recurrence was observed in 17 of 59 (28.8%) cirrhotic patients with a history of previous liver cancer during a 24-week follow-up period [5] .
In contrast to these studies, a French prospective cohort study did not observe an increased risk of HCC recurrence after DAA therapy in patients who underwent curative HCC treatment: the rates of recurrence were similar when comparing 189 patients who received DAAs (recurrence, n = 24; incidence, 8.8%/year) to 78 patients who did not receive DAAs (recurrence, n = 16; incidence, 7.9%/year) [10] . A Canadian group examined the effect of HCV eradication pre-and post-liver transplantation (LT) and reported that the treatment of HCV with DAAs prior to LT (n = 13) enabled an SVR to be achieved in 92.3% of patients with no influence on the HCC progression or mean waiting time [14] . In 2017, Zanetto et al. [15] examined the dropout rate from an LT waiting list because of HCC progression in HCV-infected patients treated with DAAs. They reported that 2 of 23 DAA-treated patients (8.7%) and 1 of 23 controls (4.3%) were registered as dropout events due to HCC progression (P = 0.90) and concluded that HCV eradication did not seem to be associated with an increased risk of dropout from the waiting list.
Several such studies have been reported from Japan . Minami et al. [13] examined the recurrence of HCC after RFA treatment and noted no difference in the rate or aggressiveness of recurrence between cases treated withs DAA (n = 27) and those treated with interferon (n = 38) within 2 years after ablation. Ikeda et al. showed that the 1-and 2-year recurrence rates after curative treatment for HCC were 18.1% and 25.0%, respectively, in patients with DAA therapy and 21.8% and 46.5%, respectively, in those without DAA therapy [9] . Nagata et al. [7] showed that the rate of cumulative HCC recurrence in patients with an SVR after interferon-free therapy was 28.9% (22/76) during a median follow-up period of 2.3 years and concluded that the risks of early HCC recurrence after viral eradication were similar between interferon-based and interferon-free therapies. However, the populations of the studies were small, and the follow-up periods were short. We therefore tried to eliminate these problems as much as possible by increasing the number of cases and prolonging the observation period.
In the period before the DAA era at our institution, the 1-, 3-and 5-year recurrence rates of HCC patients after RFA were 23.8%, 56.2% and 68.0%, respectively [19] . A study from Korea [20] reported that the 1-, 3-and 5-year cumulative intrahepatic distant recurrence rates were 24.4%, 59.5% and 73.1%, respectively. These recurrence rates were quite similar to those of our study of DAA-treated patients. Considering that the subjects in these studies were limited Nagata et al . [7] 83 N/A SVR: 22.9%/3 years Non-SVR: 40.0%/3 years
years
Ikeda et al . [9] 89 Hepatectomy 43 RFA 38 TACE 4 PRT 4
21.8%/2years 20.7 months ANRS [10] 189 N/A 8.8%/year 20.2 months
Minami et al . [13] 27 RFA 27 29.8%/2 year 1.3 years Table 6 . Summary of hepatocellular carcinoma recurrence in patients administered direct-acting antivirals after hepatocellular carcinoma treatment HCC: hepatocellular carcinoma; DAA: direct-acting antiviral; TACE: transcatheter arterial chemoembolization; PRT: particle radiation therapy; RFA: radio-frequency ablation; SVR: sustained virological response to patients with HCC at the initial treatment and that 39% of the patients in our study had recurrent HCC, we concluded that DAA treatment did not induce recurrence more frequently than interferon treatment, as we found that a history of multiple treatments for HCC before DAA therapy was an important risk factor for recurrence after DAA therapy.
We previously reported that AFP > 10 ng/mL after RFA for HCC is a significant risk factor for recurrence [21] . In the present study, however, AFP elevation before DAA treatment was not extracted as a significant factor for HCC recurrence. The discrepancy may be due to the small number of high-AFP cases in the present study due to curative treatment and the suppression of carcinogenic potential by DAA therapy. The median AFP values before and after DAA treatment were 8.4 ng/mL and 5.3 ng/mL, respectively, in the present study. Of note, however: the recurrence rate was higher in patients with high AFP-L3 levels at the initiation of DAA therapy than in patients with low AFP-L3 levels. High AFP-L3 levels are known to indicate that the HCC has a high malignant carcinogenic potential and is associated with a poor prognosis [22] . Although most published studies did not report the AFP-L3 levels of their patients, it is possible that case studies showing high recurrence rates after DAA included patients with high AFP-L3 levels.
We experienced two HCC patients who showed recurrence with portal vein invasion. Considering that both patients had a history of multiple treatments and the frequency of such a recurrence pattern was not high, it is difficult to conclude whether or not DAA treatment was responsible for this type of recurrence. Careful observation will be necessary in order to confirm whether or not the prevalence of such cases will increase in the future.
Our study was associated with some limitations. First, although the observation period was relatively long among studies in which DAA therapy was administered after curative treatment of HCC, the duration was still not sufficient to estimate the long-term survival. Second, the number of deaths was extremely small; thus, the effect of DAA therapy on prolonging the survival could not be evaluated. In addition, some factors affecting the recurrence of HCC, such as alcohol consumption and coexisting diabetes mellitus, have not been well studied.
In conclusion, the recurrence rate in patients treated with DAAs after curative treatment of HCC was comparable to that before the DAA era. We also found that multiple tumors at the first HCC treatment, a history of multiple treatments for HCC, and high AFP-L3 at the time of DAA treatment were risk factors for HCC recurrence. Given that the incidence of recurrence after DAA therapy was non-negligible, a long-term follow-up is necessary to ensure a long survival, especially for patients who have risk factors for recurrence.
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